We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 132

Materiality Part II: Government Knowledge
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • January 3 2018

This is the second in a five-part series on how U.S. district courts and courts of appeal have applied the materiality standard set forth in Universal


Metallizing Forfeiture Post-Helsinn
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • June 13 2017

In Helsinn Healthcare S.A. V. Teva Pharmaceuticals USA, Inc., the Federal Circuit had its first opportunity to address the impact of the


New York AG Takes Enforcement Action Against Heart Monitoring Apps: Murmurs of Concern are Heard in mHealth App World
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 5 2017

In a move sure to cause murmurs in the large and growing mobile health application industry, the Office of New York Attorney General Eric Schneiderman


Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • October 14 2016

After several years of delay, FDA announced this summer that it expects to publish new rules in April 2017 that will permit generic drug companies to


Forget About Vermont!: Congress Passes GMO “Labeling” Legislation
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 19 2016

On July 14, 2016, the House of Representatives passed S.764 creating a National Bioengineered Food Standard. Importantly for food manufacturers and


En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract Manufacturers
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 13 2016

Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the


En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract Manufacturers
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 13 2016

Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the


PTO Cancer Immunotherapy Fast Track
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 6 2016

In response to President Obama’s National Cancer Moonshot initiative to eliminate cancer, the USPTO has launched the “Cancer Immunotherapy Pilot


GAO Tackles Cybersecurity
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • June 30 2016

In two recent decisions, GAO denied protest grounds challenging the ability of contract awardees to satisfy government requirements related to


Second Circuit Narrowly Applies Supreme Court’s Decision in Omnicare
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 1 2016

In In re Sanofi Securities Litigation, No. 15-588-cv, 2016 U.S. App. LEXIS 4107 (2d Cir. Mar. 4, 2016), the United States Court of Appeals for the